LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aktien・Pulmatrix Inc

Pulmatrix Inc

Geschlossen

1.29 -4.44

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.25

Max

1.35

Schlüsselkennzahlen
By Trading Economics
Einkommen	-51K -928K
EPS	-0.254
Angestellte	2
EBITDA	-51K -928K

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6.6M 4.8M
Vorheriger Eröffnungskurs	5.73
Vorheriger Schlusskurs	1.29

Pulmatrix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Mai 2026, 23:58 UTC

Ergebnisse

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. Mai 2026, 22:57 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. Mai 2026, 23:52 UTC

Ergebnisse

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. Mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. Mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. Mai 2026, 23:11 UTC

Ergebnisse

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. Mai 2026, 23:06 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. Mai 2026, 23:05 UTC

Ergebnisse

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. Mai 2026, 23:04 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. Mai 2026, 23:02 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. Mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. Mai 2026, 22:42 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. Mai 2026, 22:33 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. Mai 2026, 22:32 UTC

Ergebnisse

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie: 68% of FY Income From International >MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. Mai 2026, 22:29 UTC

Ergebnisse

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. Mai 2026, 22:26 UTC

Ergebnisse

Macquarie to End Share Buyback Extended in November>MQG.AU

7. Mai 2026, 22:25 UTC

Ergebnisse

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer-Vergleich

Kursveränderung

Pulmatrix Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pulmatrix Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.